本文選題：革蘭陰性菌 + 異質(zhì)性耐藥�。� 參考：《基因組學(xué)與應(yīng)用生物學(xué)》2017年09期

【摘要】：由于抗菌藥物的廣泛應(yīng)用和不合理使用,細菌耐藥進展越來越快,遏制細菌的進一步耐藥迫在眉睫,研究發(fā)現(xiàn)異質(zhì)性耐藥是一種特殊的耐藥形式,是細菌耐藥進化的中間過程。目前許多臨床工作者對異質(zhì)性耐藥的認識較局限,并且異質(zhì)性耐藥在臨床常規(guī)藥敏試驗中多檢測為假敏感,誤導(dǎo)醫(yī)生治療用藥,是導(dǎo)致臨床感染治療失敗的重要原因。研究異質(zhì)性耐藥,對于細菌耐藥的預(yù)防、控制和指導(dǎo)臨床用藥具有重要意義。革蘭陰性菌是院內(nèi)感染的主要病原菌,為了進一步加深對該類細菌異質(zhì)性耐藥的全面認識,現(xiàn)將國內(nèi)外常見的革蘭陰性桿菌異質(zhì)性耐藥的研究進展綜述如下。
[Abstract]:Due to the wide application and irrational use of antimicrobial agents, bacterial drug resistance is developing more and more rapidly, and it is urgent to contain the further drug resistance of bacteria. It is found that heterogeneous drug resistance is a special form of drug resistance, which is the intermediate process of bacterial drug resistance evolution. At present, many clinical workers have limited understanding of heterogeneous drug resistance, and the detection of heterogeneity drug resistance in clinical routine drug sensitivity test is false sensitivity, misleading doctors to treat drug use, which is an important reason leading to the failure of clinical infection treatment. The study of heterogeneous drug resistance is of great significance for the prevention, control and guidance of bacterial drug resistance. Gram-negative bacteria are the main pathogens of nosocomial infection. In order to further understand the heterogeneity resistance of Gram-negative bacilli, the research progress of Gram-negative bacilli heterogeneity resistance at home and abroad is summarized as follows.
【作者單位】： 重慶醫(yī)科大學(xué)附屬第一醫(yī)院檢驗科實驗室;
【基金】：國家自然科學(xué)基金面上項目(81471992)資助
【分類號】：R446.5

【相似文獻】

相關(guān)期刊論文 前1條

1 侯琦;細菌的異質(zhì)性耐藥[J];臨床輸血與檢驗;2003年03期

相關(guān)碩士學(xué)位論文 前2條

1 許磊;銅綠假單胞菌多粘菌素異質(zhì)性耐藥及聯(lián)合藥敏研究[D];浙江大學(xué);2016年

2 孫繼德;無菌體液中大腸埃希菌碳青霉烯異質(zhì)性耐藥的流行病學(xué)調(diào)查及獨立危險因子分析[D];重慶醫(yī)科大學(xué);2014年

，

本文編號：1904262